Breast Cancer
Conference Coverage
After 48 years, NCI aims to track breast cancer recurrences
From the Journals
U.S. mothers underestimate role breastfeeding plays in curbing breast cancer
Only 36% of U.S. mothers currently breastfeed as recommended.
Conference Recap
Updates in HER2-positive Metastatic Breast Cancer Clinical Trials from SABCS 2020
Dr. Sara Hurvitz shares updates in HER2-positive metastatic breast cancer clinical trials from the 2020 San Antonio Breast...
Conference Coverage
Study: Doctors underreport side effects of breast irradiation
A large study shows a mismatch between patient and physician reports of toxicity.
Conference Coverage
No edge for anastrozole over tamoxifen in DCIS
Breast cancer recurrence rates were similar at almost 12 years of follow-up.
Commentary
Reproductive Rounds: Fertility preservation options for cancer patients
These two diseases intersect in the burgeoning field of oncofertility, the collaboration of oncology with reproductive endocrinology to offer...
Conference Coverage
Long-term APBI cosmetic, toxicity data reported
Conference Coverage
Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients
PRIME-2 study results show no drop in overall survival from omitting postop radiotherapy in older women with HR+, low-risk, early-stage breast...
News from the FDA/CDC
Margetuximab approved for HER2-positive metastatic breast cancer
The monoclonal antibody margetuximab-cmkb demonstrated superiority over trastuzumab.
Feature
Most common cancer diagnosis globally: Breast surpasses lung
Conference Coverage
An all-oral option for advanced HR+, HER2– breast cancer?
Adding the oral taxane tesetaxel to capecitabine improved progression-free survival.